QUESTION 1 DOES ORAL ACICLOVIR IMPROVE CLINICAL OUTCOME IN IMMUNOCOMPETENT CHILDREN WITH PRIMARY HERPES SIMPLEX GINGIVOSTOMATITIS?
A 3-year-old previously well boy presents with a fever of 38.6uC and several ulcers and erosions extending from his lips, along the tongue and cheek, to the back of the throat. The lesions have all appeared within the last 2 days. He has been crying inconsolably over the past 24 h and is refusing food and drink. Considering the current evidence we question whether the use of oral aciclovir is indicated for primary herpes gingivostomatitis in children.
STRUCTURED CLINICAL QUESTION
In an immunocompetent child presenting with primary herpes simplex gingivostomatitis [patient] , does oral aciclovir [intervention] reduce the duration of symptoms [outcome]?
SEARCH STRATEGY AND OUTCOME Cochrane Library: using ''herpes AND gingivostomatitis AND aciclovir/acyclovir'', ''herpes AND gingivostomatitis'', ''herpes AND aciclovir'', ''aciclovir AND gingivostomatitis'': one relevant result -''Acyclovir for treating primary herpetic gingivostomatitis'' -currently in title stage (registered 23 May 2007).
PubMed: with no limits set using ''herpes AND gingivostomatitis AND aciclovir'', and ''gingivostomatitis AND aciclovir'' 24 publications were found. Fifteen were not relevant or unavailable in English. Two were letters. Two studies were relevant. 1 2 Five publications were review articles. [3] [4] [5] [6] [7] These five articles were scrutinised for relevant primary research citations which were not elicited directly by the PubMed search. Three such articles were found. [8] [9] [10] Medline using OVID interface (1950 to August week 5 2007): with no limits set using ''herpes AND gingivostomatitis AND aciclovir'', and ''gingivostomatitis AND aciclovir'' 17 publications were found. Ten were not relevant or unavailable in English. Two articles were letters. Five articles were relevant; four of these articles had been identified in previous searches. 1-3 5 One new review article was identified which contained no new relevant primary research citations 11 See table 1.
Making science of the art
In the window of the Wellcome Collection in London artists work to interpret and explain science: it's an impressive experience for the irregular visitor. When faced with the presenting problems of a child and family, we are faced with trying to do the reverse. We have the sometimes inaccurate recollections of history, the variable responses of clinical examination and our own bias-riddled minds to bash through the ''art of diagnosis'' into a suitable explanation for the predicament and onwards into a management strategy. Can this really be evidence based?
The evidence base of diagnosis has been discussed in this column before, 1, 2 but usually in the setting of a single item, for example ''How good is Bobbinogs sign at predicting rhotic consonant pronunciation?''. This issue of Archimedes sees a review of clinical decision rules -simple combinations of clinically and laboratory parameters which are intended to more accurately and reliably make or exclude a diagnosis.
There are a few critical elements to bear in mind when appraising a clinical decision rule: its method of derivation, its usefulness when applied in different settings and its predictive ability. 3 A decision rule is usually developed by taking a set of data and seeing which are the simplest rules that lead to defining groups at lowest and highest risk of a disease. This method is entirely dependent on the data it is made from -any chance associations will be impossible to identify from this. The rule needs to be tested again, either in the same place (OK) or in a different setting (better). (Different doctors, types of patients and situations can make a rule unusable. This may be particularly true of rules including elements of physical examination or history taking.) Confidence in a rule should be even better still if it has been tested in many different areas and actually proven to make a difference to patient-important outcomes. Finally, a judgement needs to be made about its predictive ability. Do you need it to make a diagnosis or exclude one? (Most rules are developed to do one, or the other, but not both.) How certain do you need to be of this? These are factors that require assimilation of the risks, patient preferences and healthcare structures in your own location.
Clinical decision rules can improve health care decisions, 4 but they don't always, 5 and like all clinical research, require appraisal before use. 
COMMENTARY
Primary herpes simplex gingivostomatitis is a self-limiting condition and affected individuals may experience significant mouth pain, fever, and difficulty eating and drinking, as well as being highly infectious. 5 Although an approved treatment, retrospective data suggest that aciclovir is used infrequently in the management of this condition. 7 Aciclovir may cause a range of adverse effects including nausea, vomiting, diarrhoea and headaches, and is also a relatively expensive drug requiring administration five times a day (although cost has dropped substantially since its patent expired; for a 7-day course the cost is currently £9.21). 12 13 Concerns have been expressed regarding the possible selection of resistant strains of herpes with aciclovir being used for such common disorders. This is thought to be unlikely as, in a study of immunocompetent children receiving aciclovir for over 6 years, no resistant strains were identified.
14 Earlier and more severe recurrences of genital herpes have been demonstrated in subjects who received aciclovir during their primary illness. This is thought to be as a result of a decreased antibody response to herpes simplex viral proteins in such patients. 15 16 Nevertheless, no study identified has demonstrated this phenomenon in patients treated with a short course of aciclovir, as would be the case for primary herpes simplex gingivostomatitis.
No class I evidence was found in regard to the treatment of children presenting later than 96 h from symptom onset. In subjects presenting early (within 72 or 96 h), three small randomised controlled trials have demonstrated reduced symptom duration and faster lesion healing in patients treated with a course of oral aciclovir as compared to subjects treated with placebo, 1 8 9 findings which are broadly supported by two non-blinded retrospective studies. 2 10 There is no consensus as to the optimum length of treatment and dose of aciclovir. None of the studies have examined the side-effect profile in relation to concomitant therapeutic gain, so evidence based risk-benefit analysis remains difficult. Concern has also been expressed about the lack of data supporting the use of oral aciclovir in younger children. 3 Two population analyses have found aciclovir to be well tolerated in children under 2 years of age in dosing regimens consistent with those used in the three randomised controlled trials discussed. 17 18 Despite there being no consensus as to the treatment of immunocompetent children with primary herpes gingivostomatitis, the limited data available suggest that, while being moderately expensive, oral aciclovir given early on, reduces the duration of symptoms and infectivity of affected individuals, without causing unacceptably severe or frequently occurring side effects or long term sequelae. Duration of oral lesions Duration of pain 90% free of pain and oral lesions after 6 days of treatment and afebrile after 3 days of treatment. Treatment considered ''good or very good'' in 85% of children Subjective outcome measures limit validity of findings *Where studies were not published fully in English, information regarding the age range of children included in analysis was not always available. HSV, herpes simples virus.
QUESTION 2 DISTINGUISHING BETWEEN TRANSIENT SYNOVITIS AND SEPTIC ARTHRITIS IN THE LIMPING CHILD: HOW USEFUL ARE CLINICAL PREDICTION TOOLS?
A 3-year-old boy presents to the emergency department with a limp. He has been reluctant to weight bear on his right leg during the day and has a temperature of 37. SEARCH STRATEGY AND OUTCOME 
COMMENTARY
Distinguishing between septic arthritis and transient synovitis of the hip joint in the limping child can be a difficult clinical undertaking but is vital. The two conditions can present with similar symptoms and clinical features but the treatment and potential for negative sequelae are significantly different. Whereas transient synovitis runs a benign self-limiting course that can be managed with observation and NSAIDS, septic arthritis needs urgent diagnosis, operative irrigation and antibiotics. Poor outcomes are associated with diagnostic delays, and negative sequelae include osteonecrosis of the femoral head, growth arrest and sepsis. 1 2 There is much debate amongst clinicians over how best to accurately and quickly distinguish septic arthritis from transient synovitis with no one pathognomonic symptom, clinical feature, blood test or investigation confirming the diagnosis.
If there is sufficient clinical suspicion of septic arthritis, the hip joint must be aspirated under image guidance (ultrasound or fluoroscopy) and the fluid sent for laboratory examination. Joint aspiration is considered the gold standard test but is an invasive and unpleasant procedure, particularly for a child, usually requiring general anaesthesia. (table 2) were still most likely to predict the outcome of septic arthritis, with a diminished, but nevertheless good, diagnostic performance in the new patient population (93% probability with all four predictors present). 6 Luhmann et al, in another tertiary children's hospital, applied the same proposed CPR retrospectively on all children who had undergone aspiration of the hip joint as part of their work-up for acute hip pain. 4 Despite similar patient demographics, they found a lower predicted probability of septic arthritis (59%) when all four variables were present. These findings emphasise the value of validating all clinical prediction rules prior to application in clinical practice. Caird et al published a validation study of Kocher's CPR, including 48 children presenting with signs and symptoms suspicious enough to warrant ultrasound-guided hip aspiration. The findings supported Kocher's model to a certain extent: the likelihood of a patient having septic arthritis increased with the number of positive factors; however, the predicted probability of septic arthritis with none of the predictors present was still 16.9%.
The retrospective derivation study by Jung et al 7 included 97 patients with transient synovitis and 27 with septic arthritis. There are two main issues with their methodology. Firstly, not all patients included in the study underwent the golden standard investigation. Secondly, only patients with a positive synovial culture were definitely diagnosed with septic arthritis, oddly leaving joints with a positive microscopy (ie, synovial aspirate white cell count .50 000 ml 21 ) but negative culture possibly classified as transient synovitis. Finally, Jung's rule has not been externally validated. 
Clinical bottom line

